BHVN News

The average of price targets set by Wall Street analysts indicates a potential upside of 43.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively...

Today’s market spotlight spans companies navigating critical catalysts; NeOnc Technologies Holdings (NASDAQ:NTHI) is drawing attention with brain-cancer research milestones and a closely watched technical rebound setup; BIO-key International, (NASDAQ:BKYI) is expanding its government cybersecurity footprint in the Gulf; STAK (NASDAQ:STAK) is working to build on a return to profitability; Biohaven (NYSE:BHVN) faces pivotal clinical and regulatory questions across its drug pipeline; Exascale Labs Holdings (NASDAQ:XLAB) is pursuing AI infrastructure growth following a multimillion-dollar GPU server agreement; and WISeSat.Space (NASDAQ:SAIQ) is advancing satellite-based cybersecurity and post-quantum communications.

The U.S. Food and Drug Administration accepted Biohaven’s resubmitted application for its experimental neurological disease drug, Vyglxia.

Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. Theread more...

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select...

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx...

Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)PR NewswireNEW YORK, Sept. 11, 2026Biohaven shares gave up nearly 15% in a single...